322 related articles for article (PubMed ID: 24060335)
1. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
3. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
4. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
5. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
6. Impact of external price referencing on medicine prices - a price comparison among 14 European countries.
Leopold C; Mantel-Teeuwisse AK; Seyfang L; Vogler S; de Joncheere K; Laing RO; Leufkens H
South Med Rev; 2012 Dec; 5(2):34-41. PubMed ID: 23532710
[TBL] [Abstract][Full Text] [Related]
7. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
8. Determinants of branded prescription medicine prices in OECD countries.
Kanavos PG; Vandoros S
Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
[TBL] [Abstract][Full Text] [Related]
9. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
10. Differences in external price referencing in Europe: a descriptive overview.
Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
[TBL] [Abstract][Full Text] [Related]
11. A pricing policy towards the sourcing of cheaper drugs in Cyprus.
Merkur S; Mossialos E
Health Policy; 2007 May; 81(2-3):368-75. PubMed ID: 16949176
[TBL] [Abstract][Full Text] [Related]
12. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
13. The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis.
Zhang W; Guh DP; Grootendorst P; Hollis A; Anis AH
Health Policy; 2024 Jun; 144():105064. PubMed ID: 38608459
[TBL] [Abstract][Full Text] [Related]
14. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
15. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.
Moye-Holz D; Vogler S
Appl Health Econ Health Policy; 2022 Jan; 20(1):67-77. PubMed ID: 34228312
[TBL] [Abstract][Full Text] [Related]
17. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
18. International comparison of generic medicine prices.
Simoens S
Curr Med Res Opin; 2007 Nov; 23(11):2647-54. PubMed ID: 17877848
[TBL] [Abstract][Full Text] [Related]
19. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
